Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals has updated the market on its ongoing employee share scheme buy-back, confirming that 6,928,586 ordinary fully paid shares were repurchased on the previous trading day, with no shares bought back before that date. The daily notification underscores the company’s active capital management via buy-backs under its employee equity arrangements, which can influence its share structure and may have implications for existing shareholders’ ownership percentages and the liquidity of BOT shares.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an ASX-listed pharmaceutical company focused on developing and commercialising therapeutics, with its ordinary fully paid shares traded under the ticker BOT on the Australian Securities Exchange.
Average Trading Volume: 5,606,992
Technical Sentiment Signal: Sell
Current Market Cap: A$237M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.